ClinicalTrials.gg
CompletedNCT03776240TROIKA-1Updated Jul 7, 2026Results posted

A Study to Demonstrate the Equivalent Pharmacokinetic Properties of a Single Intravenous Dose of HD201 and EU-Herceptin® and US-Herceptin® in Healthy Male Subjects

A Phase 1 interventional study of HD201 and EU-Herceptin in Healthy Volunteers, sponsored by Prestige Biopharma Limited. Completed at 1 site in Australia. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-07.

Sponsored by Prestige Biopharma Limited · Phase 1, Interventional, and Screening

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
105
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

The purpose of the study is to demonstrate demonstrate the pharmacokinetic (PK) similarity of HD201 to the European (EU) and American (US) reference products Herceptin, following a single i.v. infusion of 6 mg/kg in healthy volunteers.

Read the detailed description

This is a double-blind, randomised, parallel group study, where a total of 105 healthy adult male volunteers, ≥ 18 and ≤ 55 years of age, non-smoker, will be dosed; 35 subjects per treatment group, randomly assigned to one of the 3 treatment arms.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • randomized
  • double-blind
03

In context

Lead sponsor

Prestige Biopharma Limited is the lead sponsor of 6 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male, non-smoker (no use of tobacco products within 3 months prior to screening), ≥ 18 and ≤ 55 years of age, with > 18.5 and \< 30.0 kg/m2 and body weight ≥ 50.0 kg.
  2. Healthy as defined by:

    1. the absence of illness and surgery within 4 weeks prior to dosing. Inclusion pre-dosing is at the discretion of the Principal Investigator.
    2. the absence of clinically significant history of neurological, endocrinal, cardiovascular, pulmonary, hematological, immunologic, psychiatric, gastrointestinal, renal, hepatic, and metabolic disease.
    3. a within the normal range as measured by echocardiogram (ECHO) within 4 weeks prior to randomization.
    4. the absence of clinically significant history of anaphylaxis, angioedema, interstitial pneumonitis, or acute respiratory distress syndrome.
  3. Male subjects who are not vasectomized for at least 6 months, and who are sexually active with non-sterile female partner [sterile female partners include women (absence of menses for 12 months prior to drug administration) or women who have had a tubal ligation, hysterectomy, or bilateral oophorectomy (at least 6 months prior to drug administration)] must be willing to use one of the following acceptable method throughout the study and for 90 days after the last study drug administration:

    1. simultaneous use of condom, and for the female partner hormonal contraceptives (used since at least 4 weeks) or intra-uterine contraceptive device (placed since at least 4 weeks);
    2. simultaneous use of male condom, and for the female partner, diaphragm with intravaginally applied spermicide.
  4. Male subjects, including men who have had vasectomy, with a pregnant partner must agree to use a condom throughout the study and for 90 days after the last study drug administration.
  5. Male subjects must be willing not to donate sperm until 90 days following the last study drug administration.
  6. Capable of consent.

Exclusion criteria

Exclusion Criteria:

f the following applies will be excluded from the study:

  1. Any abnormality or abnormal laboratory test results found during medical screening or positive test for , , or found during medical screening.
  2. Positive urine drug screen at screening.
  3. History of allergic reactions to trastuzumab, benzyl alcohol, murine proteins, or other related drugs.
  4. Any reason which, in the opinion of the Principal Investigator, would prevent the subject from participating in the study.
  5. Clinically significant abnormalities ( >450 ms) and or vital sign abnormalities (systolic blood pressure lower than 90 or over 140 mmHg, diastolic blood pressure lower than 50 or over 90 mmHg, or heart rate less than 50 or over 100 bpm) at screening.
  6. History of significant alcohol abuse within one year prior to screening or regular use of alcohol within six months prior to the screening visit (more than fourteen units of alcohol per week [1 unit = 150 mL of wine, 360 mL of beer, or 45 mL of 40% alcohol]).
  7. History of significant drug abuse within one year prior to screening or use of soft drugs (such as marijuana) within 3 months prior to the screening visit or hard drugs (such as cocaine, phencyclidine [PCP], crack, opioid derivatives including heroin, and amphetamine derivatives) within 1 year prior to screening.
  8. Previous use of trastuzumab or another monoclonal antibody for a medical condition or in the context of another clinical trial.
  9. Participation in a clinical research study involving the administration of an or marketed drug or device within 30 days prior to the first dosing, administration of a biological product in the context of a clinical research study within 90 days prior to the first dosing, or concomitant participation in an investigational study involving no drug or device administration.
  10. Use of medication other than topical products without significant systemic absorption:

    1. prescription medication within 14 days prior to dose administration;
    2. over-the-counter products including natural health products (e.g. food supplements and herbal supplements) within 7 days prior to dosing, with the exception of the occasional use of acetaminophen (paracetamol - up to 2 g daily);
    3. a depot injection or an implant of any drug within 3 months prior to dose administration.
  11. Donation of plasma within 7 days prior to dosing. Donation or loss of blood (excluding volume drawn at screening) of 50 mL to 499 mL of blood within 30 days, or more than 499 mL within 56 days prior to the first dosing.
  12. \< 12.8 g/dL and hematocrit \< 0.37 L/L at screening.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 1
Primary purpose
Screening
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
105 participants (actual)

Study arms

  • Experimental
    HD201

    Trastuzumab Single-dose 6mg/kg body weight by 90 minute intravenous infusion

    Drug: HD201

  • Active comparator
    EU-licensed Herceptin

    Trastuzumab Single-dose 6mg/kg body weight by 90 minute intravenous infusion

    Drug: EU-Herceptin

  • Active comparator
    US-licensed Herceptin

    Trastuzumab Single-dose 6mg/kg body weight by 90 minute intravenous infusion

    Drug: US-Herceptin

Interventions

  • DrugHD201

    Single-dose 6mg/kg body weight by 90 minute intravenous infusion

    Also known as: Trastuzumab

  • Single-dose 6mg/kg body weight by 90 minute intravenous infusion

    Also known as: Trastuzumab

  • Single-dose 6mg/kg body weight by 90 minute intravenous infusion

    Also known as: Trastuzumab

06

What researchers measure

Primary outcomes

  1. Trastuzumab Serum PK Parameter (AUC0-inf)

    Sampling will be performed in all patients to compare PK though values of HD201 and Herceptin. Samples were collected from 0-1272 hours on Days 1-54.

    Time frame: Up to day 54

  2. Trastuzumab Serum PK Parameter (AUC0-last)

    Sampling will be performed in all patients to compare PK though values of HD201 and Herceptin

    Time frame: Up to Day 54

  3. Trastuzumab Serum PK Parameter (Cmax)

    Sampling will be performed in all patients to compare PK though values of HD201 and Herceptin

    Time frame: Up to Day 54

07

Results

Posted Jul 7, 2026

Participant flow

Participant flow — Overall Study
MilestoneHD201EU-licensed HerceptinUS-licensed Herceptin
Started353535
Completed333332
Not completed223
Withdrew: Withdrawal by subject223

Outcome measures

PrimaryTrastuzumab Serum PK Parameter (AUC0-inf)

Sampling will be performed in all patients to compare PK though values of HD201 and Herceptin. Samples were collected from 0-1272 hours on Days 1-54.

Time frame:
Up to day 54
Reported as:
Geometric mean · h*μg/mL
Trastuzumab Serum PK Parameter (AUC0-inf)
h*μg/mLHD201EU-licensed HerceptinUS-licensed Herceptin
Trastuzumab Serum PK Parameter (AUC0-inf)38350.2 ± 16.037432.7 ± 16.737298.5 ± 15.5
Statistical analysis
  • HD201 vs EU-licensed Herceptin · Geometric mean ratio: 102.45 · 90% CI 95.95 to 109.40
  • EU-licensed Herceptin vs US-licensed Herceptin · Geometric mean ratio: 100.36 · 90% CI 93.94 to 107.22
  • HD201 vs US-licensed Herceptin · Geometric mean ratio: 102.82 · 90% CI 96.15 to 109.96
PrimaryTrastuzumab Serum PK Parameter (AUC0-last)

Sampling will be performed in all patients to compare PK though values of HD201 and Herceptin

Time frame:
Up to Day 54
Reported as:
Geometric mean · h*μg/mL
Trastuzumab Serum PK Parameter (AUC0-last)
h*μg/mLHD201EU-licensed HerceptinUS-licensed Herceptin
Trastuzumab Serum PK Parameter (AUC0-last)36587.5 ± 17.635337.1 ± 17.035619.9 ± 15.3
Statistical analysis
  • HD201 vs EU-licensed Herceptin · Geometric mean ratio: 103.54 · 90% CI 96.76 to 110.80
  • EU-licensed Herceptin vs US-licensed Herceptin · Geometric mean ratio: 99.21 · 90% CI 92.65 to 106.22
  • HD201 vs US-licensed Herceptin · Geometric mean ratio: 102.72 · 90% CI 95.84 to 110.09
PrimaryTrastuzumab Serum PK Parameter (Cmax)

Sampling will be performed in all patients to compare PK though values of HD201 and Herceptin

Time frame:
Up to Day 54
Reported as:
Geometric mean · μg/mL
Trastuzumab Serum PK Parameter (Cmax)
μg/mLHD201EU-licensed HerceptinUS-licensed Herceptin
Trastuzumab Serum PK Parameter (Cmax)148.86 ± 19.5142.28 ± 15.5151.10 ± 16.6
Statistical analysis
  • HD201 vs EU-licensed Herceptin · Geometric mean ratio: 104.62 · 90% CI 97.55 to 112.20
  • HD201 vs EU-licensed Herceptin · Geometric mean ratio: 94.17 · 90% CI 87.75 to 101.05
  • HD201 vs EU-licensed Herceptin · Geometric mean ratio: 98.52 · 90% CI 91.71 to 105.82

Adverse events

Collected over All (S)AEs were to be collected from the signing of the informed consent form (ICF) until the Day 54. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
HD2010/35 (0%)0/35 (0%)18/35 (51.4%)
EU-licensed Herceptin0/35 (0%)1/35 (2.9%)23/35 (65.7%)
US-licensed Herceptin0/35 (0%)0/35 (0%)24/35 (68.6%)
Most frequent serious events
Most frequent serious events
EventHD201EU-licensed HerceptinUS-licensed Herceptin
Hand fractureInjury, poisoning and procedural complications0/351/350/35
Most frequent other events
Showing 10 of 21
Most frequent other events
EventHD201EU-licensed HerceptinUS-licensed Herceptin
HeadacheNervous system disorders11/358/357/35
Infusion related reactionInjury, poisoning and procedural complications4/357/3511/35
Upper respiratory tract infectionRespiratory, thoracic and mediastinal disorders0/352/355/35
RhinitisRespiratory, thoracic and mediastinal disorders1/350/354/35
CoughRespiratory, thoracic and mediastinal disorders1/354/350/35
LymphopeniaBlood and lymphatic system disorders0/354/351/35
PyrexiaGeneral disorders2/353/350/35
Oropharyngeal painRespiratory, thoracic and mediastinal disorders3/352/350/35
Back painMusculoskeletal and connective tissue disorders1/351/353/35
PresyncopeNervous system disorders0/350/352/35

Baseline characteristics

Age, Continuous
Age, Continuous(Years)HD201EU-licensed HerceptinUS-licensed HerceptinTotal
Mean27.5 (19 to 49)29.6 (18 to 54)29.7 (19 to 52)28.9 (18 to 54)
Sex: Female, Male
Sex: Female, Male(Participants)HD201EU-licensed HerceptinUS-licensed HerceptinTotal
Female0000
Male353535105
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)HD201EU-licensed HerceptinUS-licensed HerceptinTotal
Asian57618
Black or African American0112
Native Hawaiian or other Pacific0101
White29242376
Other1258
08

Study locations

1 site
  • Q Pharm
    Brisbane, Australia
09

References and documents

Publications

  • Demarchi M, Coliat P, Mclendon K, Chung Shii Hii J, Feyaerts P, Ang F, Jaison L, Deforce F, Derde MP, Kim MJ, Park LS, Detappe A, Pivot X. TROIKA-1: A double-blind, randomized, parallel group, study aimed to demonstrate the equivalent pharmacokinetic profile of HD201, a potential biosimilar candidate to trastuzumab, versus EU-Herceptin(R) and US-Herceptin(R) in healthy male subjects. Pharmacol Res Perspect. 2021 Aug;9(4):e00839. doi: 10.1002/prp2.839. PubMed 34309241 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2019 to primary completion in Aug 2019, 4 months.

Results were first posted in Jul 2026, 6 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2018
First posted
Dec 14, 2018
StartActual
Apr 1, 2019
Primary completionActual
Aug 19, 2019
CompletionActual
Aug 19, 2019
Results first posted
Jul 7, 2026
Last update
Jul 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03776240
Lead sponsor
Prestige Biopharma Limited
Responsible party
Sponsor
First posted
Dec 14, 2018
Start date
Apr 1, 2019
Primary completion
Aug 19, 2019
Completion
Aug 19, 2019
Results posted
Jul 7, 2026
Last update
Jul 7, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trastuzumab

Start the discussion